|Grant Number:||5R01CA131010-03 Interpret this number|
|Primary Investigator:||Capanu, Marinela|
|Organization:||Sloan-Kettering Inst Can Res|
|Project Title:||Estimating Cancer Risks of Rare Genetic Variants|
DESCRIPTION (provided by applicant): It is now well established that many genes influence the risk of cancer. For major genes known to affect risk, an important task is to determine the risks conferred by individual variants. Geneticists consider variants to confer risk if they have been shown to segregate with disease in families, but increasingly the evidence will accrue from population-based association studies, where empirical evidence is obtained on the basis of case and control frequencies for all observed variants, many of which will necessarily occur very infrequently, perhaps only once, in the study. Furthermore, many of these variants will not have been observed in previous cancer-prone families. Hierarchical modeling offers a natural strategy to leverage the collective evidence from these rare variants with sparse data. This can be accomplished when the variants can be effectively grouped on the basis of higher- level covariates that characterize the functional properties of the variants that are relevant to risk prediction. In this application we propose to study in detail the properties of available hierarchical modeling techniques for this purpose, and suitable modifications of these techniques, with a view to establishing valid analytic strategies for obtaining relative risk estimates for rare variants. We will use simulations to evaluate the small sample properties of pseudo-likelihood estimation of the relative risks of rare variants from a hierarchical model. The simulations will address bias and cover- age probabilities of the individual estimators, their relative efficiency compared to ordinary logistic regression, the influence of the predictiveness of the higher-level covariates, the impact of model misspecification, the influence of sample size, the impact of missing data on higher-level covariates, and the use of explained variation as a measure of extent to which the higher-level covariates explain the risk variation. We will also examine the asymptotic properties of pseudo-likelihood estimation under various assumptions: a correctly specified hierarchical model; an incorrectly specified hierarchical model; and a setting in which the number of variants is allowed to increase indefinitely, but data on the individual variants remains sparse. These investigations address distinct questions of practical importance in the design and analysis of association (case-control) studies of major cancer genes. PUBLIC HEALTH RELEVANCE: Many major genes have been identified that strongly in0uence the risk of cancer. However, there are typically many different mutations in the gene, each of which may or may not confer increased risk. It is critical to identify which genetic mutations are harmful, and which ones are harmless, so that individuals who learn from genetic testing that they have a mutation can be appropriately counseled. This is a challenging task, since new mutations are continually being identified, and there is typically relatively little evidence available about each individual mutation. In this proposal we plan to examine new statistical techniques that have the potential to identify the mutations that are harmful with much greater accuracy. The research will involve hierarchical statistical modeling, a technique that aggregates the evidence about lots of rare mutations to increase the ability to predict the effects of each mutation individually.
An assessment of estimation methods for generalized linear mixed models with binary outcomes.
Authors: Capanu M, Gönen M, Begg CB
Source: Stat Med, 2013 Nov 20;32(26), p. 4550-66.
EPub date: 2013 Jul 9.
Detecting and exploiting etiologic heterogeneity in epidemiologic studies.
Authors: Begg CB, Zabor EC
Source: Am J Epidemiol, 2012 Sep 15;176(6), p. 512-8.
EPub date: 2012 Aug 24.
Risk of non-melanoma cancers in first-degree relatives of CDKN2A mutation carriers.
Authors: Mukherjee B, Delancey JO, Raskin L, Everett J, Jeter J, Begg CB, Orlow I, Berwick M, Armstrong BK, Kricker A, Marrett LD, Millikan RC, Culver HA, Rosso S, Zanetti R, Kanetsky PA, From L, Gruber SB, GEM Study Investigators
Source: J Natl Cancer Inst, 2012 Jun 20;104(12), p. 953-6.
EPub date: 2012 Apr 24.
Rare germline mutations in PALB2 and breast cancer risk: a population-based study.
Authors: Tischkowitz M, Capanu M, Sabbaghian N, Li L, Liang X, Vallée MP, Tavtigian SV, Concannon P, Foulkes WD, Bernstein L, WECARE Study Collaborative Group, Bernstein JL, Begg CB
Source: Hum Mutat, 2012 Apr;33(4), p. 674-80.
EPub date: 2012 Feb 15.
Assessment of rare BRCA1 and BRCA2 variants of unknown significance using hierarchical modeling.
Authors: Capanu M, Concannon P, Haile RW, Bernstein L, Malone KE, Lynch CF, Liang X, Teraoka SN, Diep AT, Thomas DC, Bernstein JL, WECARE Study Collaborative Group, Begg CB
Source: Genet Epidemiol, 2011 Jul;35(5), p. 389-97.
EPub date: 2011 Apr 25.
A strategy for distinguishing optimal cancer subtypes.
Authors: Begg CB
Source: Int J Cancer, 2011 Aug 15;129(4), p. 931-7.
EPub date: 2010 Nov 18.
Hierarchical modeling for estimating relative risks of rare genetic variants: properties of the pseudo-likelihood method.
Authors: Capanu M, Begg CB
Source: Biometrics, 2011 Jun;67(2), p. 371-80.
EPub date: 2010 Aug 5.
Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2.
Authors: Malone KE, Begg CB, Haile RW, Borg A, Concannon P, Tellhed L, Xue S, Teraoka S, Bernstein L, Capanu M, Reiner AS, Riedel ER, Thomas DC, Mellemkjaer L, Lynch CF, Boice JD Jr, Anton-Culver H, Bernstein JL
Source: J Clin Oncol, 2010 May 10;28(14), p. 2404-10.
EPub date: 2010 Apr 5.
Evaluating cancer epidemiologic risk factors using multiple primary malignancies.
Authors: Kuligina E, Reiner A, Imyanitov EN, Begg CB
Source: Epidemiology, 2010 May;21(3), p. 366-72.
Characterization of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: the WECARE study.
Authors: Borg A, Haile RW, Malone KE, Capanu M, Diep A, Törngren T, Teraoka S, Begg CB, Thomas DC, Concannon P, Mellemkjaer L, Bernstein L, Tellhed L, Xue S, Olson ER, Liang X, Dolle J, Břrresen-Dale AL, Bernstein JL
Source: Hum Mutat, 2010 Mar;31(3), p. E1200-40.
Variants in the ATM gene associated with a reduced risk of contralateral breast cancer.
Authors: Concannon P, Haile RW, Břrresen-Dale AL, Rosenstein BS, Gatti RA, Teraoka SN, Diep TA, Jansen L, Atencio DP, Langholz B, Capanu M, Liang X, Begg CB, Thomas DC, Bernstein L, Olsen JH, Malone KE, Lynch CF, Anton-Culver H, Bernstein JL, Women's Environment, Cancer, and Radiation Epidemiology Study Collaborative Group
Source: Cancer Res, 2008 Aug 15;68(16), p. 6486-91.
The use of hierarchical models for estimating relative risks of individual genetic variants: an application to a study of melanoma.
Authors: Capanu M, Orlow I, Berwick M, Hummer AJ, Thomas DC, Begg CB
Source: Stat Med, 2008 May 20;27(11), p. 1973-92.
Variation of breast cancer risk among BRCA1/2 carriers.
Authors: Begg CB, Haile RW, Borg A, Malone KE, Concannon P, Thomas DC, Langholz B, Bernstein L, Olsen JH, Lynch CF, Anton-Culver H, Capanu M, Liang X, Hummer AJ, Sima C, Bernstein JL
Source: JAMA, 2008 Jan 9;299(2), p. 194-201.